Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management (The TRIUMPH Study)
Neeraj Narula, Cara Pray, Hasan J. Hamam, Farhad Peerani et autres
Background: Tofacitinib is a rapidly acting Janus kinase (JAK) inhibitor with increasing evidence of effectiveness in patients with acute severe ulcerative colitis (ASUC). However, there are scarce prospective data analyzing the efficacy and rapidity of action in hospitalized ASUC. Methods: The TRIUMPH …
ca (code pays fourni par la source)